Thu, 17 Jun|
SYNBIO TALKS: Introducing CRISPR technology and its impact on the drug discovery
An event for companies, researchers, and entrepreneurs interested in learning more about CRISPR technology and how to successfully apply it to their own work.
Time & Location
17 Jun 2021, 14:00 – 15:30
About the Event
You are warmly welcome to our Synbio Talk in June!
Synbio Talks are an event series taking place every month where we talk about different topics related to synthetic biology. Our aim with these events is to build a stronger synbio community in Finland and beyond as well as to strengthen collaboration networks in the field of synthetic biology.
For this event, we will have Nick Clare from Synthego as our guest speaker. You will have the opportunity to learn about:
- Experimental key points to consider when setting up your CRISPR experiment.
- CRISPR tools that will allow for an easier and simplified CRISPR workflow.
- Leveraging CRISPR-editing platform in the generation of engineered cell lines.
- Synthego’s multi-guide design strategy to ensure loss-of-function screening of 100-1000s of genes with clear phenotypic signals and minimal false negatives and positives.
14:00 - 14:10 Welcome and Synbio Powerhouse News - Manuel Arias, Project Manager at Synbio Powerhouse
14:10 - 15:00 Introducing CRISPR technology and its impact on the drug discovery - Nick Clare, Strategic Account Manager at Synthego
15:00 - 15:20 Q&A
15:20 - 15:30 Wrap-up
We look forward to seeing you all!
CRISPR-based genome editing has largely been a manual process, enabling the generation of engineered cell lines for a multitude of applications. However, this is limiting in its scale and therefore limits the potential impact of this incredible technology.
Attempts to understand biological complexity are often limited by time, resources, and budget. Precision biology, while extremely powerful, can add months to a project timeline because these models and cells are often much more difficult to engineer. The need to identify targets and have a deeper understanding of their role in biology is critical to reducing late-stage attrition.
Often, target identification is a combination of conventional loss of function studies & genomics-based drug discovery. Performing CRISPR-based arrayed loss-of-function screens can clearly link complex disease phenotypes to genes. Technologies like CRISPR enable genome modification of multiple cell types, including pluripotent stem cells, empowering better understanding of cell and metabolic processes and offer the option to enable a deeper understanding of the target-disease relationship.
Therefore, Synthego’s focus is to work with scientists worldwide and offer knowledge, expertise, and tools to support them in their research objectives.
Nick Clare, Strategic Account Manager
Nick Clare has worked as a scientist/Lab head leading projects to establish good cell/genetic models in R&D for 18 years, in large Pharma and startups. In more recent years he has worked to support scientists in selecting the right tools and methods in stem cells and CRISPR applications.
More information: https://www.synthego.com/